Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 27;66(8):5611-5621.
doi: 10.1021/acs.jmedchem.2c02064. Epub 2023 Apr 17.

High-Contrast PET Imaging with [18F]NT160, a Class-IIa Histone Deacetylase Probe for In Vivo Imaging of Epigenetic Machinery in the Central Nervous System

Affiliations

High-Contrast PET Imaging with [18F]NT160, a Class-IIa Histone Deacetylase Probe for In Vivo Imaging of Epigenetic Machinery in the Central Nervous System

Nashaat Turkman et al. J Med Chem. .

Abstract

We utilized positron emission tomography (PET) imaging in vivo to map the spatiotemporal biodistribution/expression of class-IIa histone deacetylases (class-IIa HDACs) in the central nervous system (CNS). Herein we report an improved radiosynthesis of [18F]NT160 using 4-hydroxy-TEMPO which led to a significant improvement in radiochemical yield and molar activity. PET imaging with [18F]NT160, a highly potent class-IIa HDAC inhibitor, led to high-quality and high-contrast images of the brain. [18F]NT160 displayed excellent pharmacokinetic and imaging characteristics: brain uptake is high in gray matter regions, tissue kinetics are appropriate for a 18F-tracer, and specific binding for class-IIa HDACs is demonstrated by self-blockade. Higher uptake with [18F]NT160 was observed in the hippocampus, thalamus, and cortex while the uptake in the cerebellum was relatively low. Overall, our current studies with [18F]NT160 will likely facilitate the development and clinical translation of PET tracers for imaging of class-IIa HDACs biodistribution/expression in cancer and the CNS.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Chemical structures of radiolabeled class-IIa HDAC inhibitors.
Scheme 1
Scheme 1. Improved Radiosynthesis of [18F]NT160
Figure 2
Figure 2
Representative PET and PET/CT (fusion) images with [18F]NT160 of rat brain (summed 5–30 min): (A and B) coronal, (C and D) sagittal, and (E and F) transverse, respectively.
Figure 3
Figure 3
Time–activity curves of [18F]NT160 obtained from dynamic imaging for 60 min. (A) Brain, muscle, and heart; (B) hippocampus (Hip), cortex (Cortx), thalamus (TH), striatum (Str), and cerebellum (Cer).
Figure 4
Figure 4
Representative coronal PET images (summed, 5–30 min) with [18F]NT160 with the corresponding rat brain regions. Crt: Cortex, Cer: cerebellum, Th: thalamus, Hip: hippocampus, Str: striatum. The alignment for the images with the rat brain atlas was used to identify these regions of interest.,
Figure 5
Figure 5
(A) In vitro autoradiography with [18F]NT160 at baseline and (B) after pretreatment with NT160 (1.0 μM). (C) Brain histology obtained with HDAC4 antibody.
Figure 6
Figure 6
Time–activity curves obtained from dynamic imaging for 60 min: (A) whole brain; (B) hippocampus and cerebellum at baseline and after self-blocking. Cer: cerebellum, Hip: hippocampus.
Figure 7
Figure 7
Analytical HPLC chromatograms of [18F]NT160 obtained from (A) brain homogenates and (B) plasma. (C) Proposed blood metabolic pathway for M1 (radiometabolism of [18F]NT160 leads to [18F]1 (M1). (D and E) Inhibition of HDAC activity by compound 1 (M1) in HT-29 cells: (D) Inhibition of class-IIa HDAC and (E) inhibition of class-I/IIb. Compound 1 was screened side-by-side with SAHA and NT160.
Figure 8
Figure 8
Representative PET, CT, and PT/CT images (summed, 0–60 min) with [18F]1: (A and B) coronal, (C and D) sagittal, and (E and F) transverse, respectively. (G) Time–activity curve of [18F]1 in rat brain.

Similar articles

Cited by

References

    1. Kassis H.; Shehadah A.; Li C.; Zhang Y.; Cui Y.; Roberts C.; Sadry N.; Liu X.; Chopp M.; Zhang Z. G. Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke. Neurochemistry international 2016, 96, 24–31. 10.1016/j.neuint.2016.04.006. - DOI - PMC - PubMed
    1. Faraco G.; Pancani T.; Formentini L.; Mascagni P.; Fossati G.; Leoni F.; Moroni F.; Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Molecular pharmacology 2006, 70 (6), 1876–1884. 10.1124/mol.106.027912. - DOI - PubMed
    1. Ren M.; Leng Y.; Jeong M.; Leeds P. R.; Chuang D. M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. Journal of neurochemistry 2004, 89 (6), 1358–1367. 10.1111/j.1471-4159.2004.02406.x. - DOI - PubMed
    1. Kim H. J.; Rowe M.; Ren M.; Hong J. S.; Chen P. S.; Chuang D. M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol Exp Ther 2007, 321 (3), 892–901. 10.1124/jpet.107.120188. - DOI - PubMed
    1. Steffan J. S.; Bodai L.; Pallos J.; Poelman M.; McCampbell A.; Apostol B. L.; Kazantsev A.; Schmidt E.; Zhu Y. Z.; Greenwald M.; et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413 (6857), 739–743. 10.1038/35099568. - DOI - PubMed

Publication types

MeSH terms

Substances